Anti‑osteoporotic effects of tetramethylpyrazine via promoting osteogenic differentiation and inhibiting osteoclast formation Corrigendum in /10.3892/mmr.2023.13061

Wang,Long; Lu,Wei‑Guang; Shi,Jun; Zhang,Hong‑Yang; Xu,Xiao‑Long; Gao,Bo; Huang,Qiang; Li,Xiao‑Jie; Hu,Ya‑Qian; Jie,Qiang; Luo,Zhuo‑Jing; Yang,Liu

doi:10.3892/mmr.2017.7610

Anti‑osteoporotic effects of tetramethylpyrazine via promoting osteogenic differentiation and inhibiting osteoclast formation

Corrigendum in: /10.3892/mmr.2023.13061

Authors:
- Long Wang
- Wei‑Guang Lu
- Jun Shi
- Hong‑Yang Zhang
- Xiao‑Long Xu
- Bo Gao
- Qiang Huang
- Xiao‑Jie Li
- Ya‑Qian Hu
- Qiang Jie
- Zhuo‑Jing Luo
- Liu Yang
View Affiliations

Affiliations: Institute of Orthopedic Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
Published online on: September 25, 2017 https://doi.org/10.3892/mmr.2017.7610
Pages: 8307-8314

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long‑term glucocorticoid therapy results in various side effects, including a high incidence of glucocorticoid‑induced osteoporosis (GIOP), which is the most common form of secondary osteoporosis. Excess glucocorticoids reduce the viability of bone marrow‑derived mesenchymal stem cells (BMSCs) and prolong osteoclast survival. These two types of cell are essential in the balance between bone formation and resorption. Tetramethylpyrazine (TMP), the pharmacologically active component extracted from Chuanxiong, has been reported to protect BMSCs from glucocorticoid‑induced apoptosis. In the present study, the protective effects of TMP on BMSC differentiation and osteoclasts maturation in GIOP were investigated in vivo and in vitro. The immunostaining of osterix (OSX) and tartrate‑resistant acid phosphatase (TRAP) staining indicated that TMP promoted osteogenesis and inhibited osteoclastogenesis in a rat model of GIOP. Treatment with 10‑6 M dexamethasone (Dex) significantly inhibited BMSC differentiation and increased TRAP‑positive cells in vitro. However, different concentrations of TMP (50, 100 and 200 µM) ameliorated the negative effects of Dex by promoting the activity of alkaline phosphatase (ALP) and the calcium mineralization of BMSCs following osteogenic induction, which increased the expression levels of osteogenic genes, including ALP, collagen type I α1, osteocalcin and OSX, and decreased osteoclastogenesis‑related genes, including TRAP, nuclear factor of T‑cells cytoplasmic 1 and cathepsin K. In addition, it was found that the inhibition of receptor activator of nuclear factor‑κB ligand and intereleukin‑6 in BMSCs may be a possible mechanism for the protective effects of TMP against glucocorticoid‑induced osteoclastogenesis. These results are the first, to the best of our knowledge, to demonstrate that TMP promotes BMSC differentiation and inhibits osteoclastogenesis to ameliorate bone mass change in GIOP.

View Figures

View References

1	Hofbauer LC, Hamann C and Ebeling PR: Approach to the patient with secondary osteoporosis. Eur J Endocrinol. 162:1009–1020. 2010. View Article : Google Scholar : PubMed/NCBI
2	Rizzoli R and Biver E: Glucocorticoid-induced osteoporosis: Who to treat with what agent? Nat Rev Rheumatol. 11:98–109. 2015. View Article : Google Scholar : PubMed/NCBI
3	Canalis E, Mazziotti G, Giustina A and Bilezikian JP: Glucocorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporos Int. 18:1319–1328. 2007. View Article : Google Scholar : PubMed/NCBI
4	O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC and Weinstein RS: Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 145:1835–1841. 2004. View Article : Google Scholar : PubMed/NCBI
5	Jia D, O'Brien CA, Stewart SA, Manolagas SC and Weinstein RS: Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 147:5592–5599. 2006. View Article : Google Scholar : PubMed/NCBI
6	Harada S and Rodan GA: Control of osteoblast function and regulation of bone mass. Nature. 423:349–355. 2003. View Article : Google Scholar : PubMed/NCBI
7	Karsenty G and Wagner EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2:389–406. 2002. View Article : Google Scholar : PubMed/NCBI
8	Ash P, Loutit JF and Townsend KM: Osteoclasts derived from haematopoietic stem cells. Nature. 283:669–670. 1980. View Article : Google Scholar : PubMed/NCBI
9	Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
10	Lagasse E and Weissman IL: Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell. 89:1021–1031. 1997. View Article : Google Scholar : PubMed/NCBI
11	Bonyadi M, Waldman SD, Liu D, Aubin JE, Grynpas MD and Stanford WL: Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice. Proc Natl Acad Sci USA. 100:pp. 5840–5845. 2003; View Article : Google Scholar : PubMed/NCBI
12	Miura M, Chen XD, Allen MR, Bi Y, Gronthos S, Seo BM, Lakhani S, Flavell RA, Feng XH, Robey PG, et al: A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest. 114:1704–1713. 2004. View Article : Google Scholar : PubMed/NCBI
13	Chen TL: Inhibition of growth and differentiation of osteoprogenitors in mouse bone marrow stromal cell cultures by increased donor age and glucocorticoid treatment. Bone. 35:83–95. 2004. View Article : Google Scholar : PubMed/NCBI
14	Huang Q, Shi J, Gao B, Zhang HY, Fan J, Li XJ, Fan JZ, Han YH, Zhang JK, Yang L, et al: Gastrodin: An ancient Chinese herbal medicine as a source for anti-osteoporosis agents via reducing reactive oxygen species. Bone. 73:132–144. 2015. View Article : Google Scholar : PubMed/NCBI
15	Boyce BF: Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res. 28:711–722. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wang K, Niu J, Kim H and Kolattukudy PE: Osteoclast precursor differentiation by MCPIP via oxidative stress, endoplasmic reticulum stress, and autophagy. J Mol Cell Biol. 3:360–368. 2011. View Article : Google Scholar : PubMed/NCBI
17	Xiu Y, Xu H, Zhao C, Li J, Morita Y, Yao Z, Xing L and Boyce BF: Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J Clin Invest. 124:297–310. 2014. View Article : Google Scholar : PubMed/NCBI
18	Shi J, Wang L, Zhang H, Jie Q, Li X, Shi Q, Huang Q, Gao B, Han Y, Guo K, et al: Glucocorticoids: Dose-related effects on osteoclast formation and function via reactive oxygen species and autophagy. Bone. 79:222–232. 2015. View Article : Google Scholar : PubMed/NCBI
19	Chen L, Wei X, Hou Y, Liu X, Li S, Sun B, Liu X and Liu H: Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion-induced apoptosis through PI3K/Akt/GSK3β pathway in rats. Neurochem Int. 66:27–32. 2014. View Article : Google Scholar : PubMed/NCBI
20	Gong X, Ivanov VN, Davidson MM and Hei TK: Tetramethylpyrazine (TMP) protects against sodium arsenite-induced nephrotoxicity by suppressing ROS production, mitochondrial dysfunction, pro-inflammatory signaling pathways and programed cell death. Arch Toxicol. 89:1057–1070. 2015. View Article : Google Scholar : PubMed/NCBI
21	Yu N, Zhang Z, Chen P, Zhong Y, Cai X, Hu H, Yang Y, Zhang J, Li K, Ge J, et al: Tetramethylpyrazine (TMP), an active ingredient of Chinese herb medicine Chuanxiong, attenuates the degeneration of trabecular meshwork through SDF-1/CXCR4 axis. PLoS One. 10:e01330552015. View Article : Google Scholar : PubMed/NCBI
22	Wang L, Zhang HY, Gao B, Shi J, Huang Q, Han YH, Hu YQ, Lu WG, Zhao ZJ, Liu BH, et al: Tetramethylpyrazine protects against glucocorticoid-induced apoptosis by promoting autophagy in mesenchymal stem cells and improves bone mass in glucocorticoid-induced osteoporosis rats. Stem Cells Dev. 26:419–430. 2017. View Article : Google Scholar : PubMed/NCBI
23	Lu C, Zhang J, Shi X, Miao S, Bi L, Zhang S, Yang Q, Zhou X, Zhang M, Xie Y, et al: Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP. Int J Biol Sci. 10:350–357. 2014. View Article : Google Scholar : PubMed/NCBI
24	Bouffi C, Bony C, Courties G, Jorgensen C and Noël D: IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One. 5:e142472010. View Article : Google Scholar : PubMed/NCBI
25	Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj and Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International society for cellular therapy position statement. Cytotherapy. 8:315–317. 2006. View Article : Google Scholar : PubMed/NCBI
26	Wang X, Harimoto K, Liu J, Guo J, Hinshaw S, Chang Z and Wang Z: Spata4 promotes osteoblast differentiation through Erk-activated Runx2 pathway. J Bone Miner Res. 26:1964–1973. 2011. View Article : Google Scholar : PubMed/NCBI
27	Chen JJ, Zhang NF, Mao GX, He XB, Zhan YC, Deng HB, Song DQ, Li DD, Li ZR, Si SY, et al: Salidroside stimulates osteoblast differentiation through BMP signaling pathway. Food Chem Toxicol. 62:499–505. 2013. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Wang L, Fan J, Lin YS, Guo YS, Gao B, Shi QY, Wei BY, Chen L, Yang L, Liu J and Luo ZJ: Glucocorticoids induce autophagy in rat bone marrow mesenchymal stem cells. Mol Med Rep. 11:2711–2716. 2015. View Article : Google Scholar : PubMed/NCBI
30	Cui L, Li T, Liu Y, Zhou L, Li P, Xu B, Huang L, Chen Y, Liu Y, Tian X, et al: Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis. PLoS One. 7:e346472012. View Article : Google Scholar : PubMed/NCBI
31	Hu J, Cao Y, Wu T, Li D and Lu H: Micro-CT as a tool to investigate the efficacy of tetramethylpyrazine in a rat spinal cord injury model. Spine (Phila Pa 1976). 41:1272–1278. 2016. View Article : Google Scholar : PubMed/NCBI
32	Gao B, Huang Q, Jie Q, Zhang HY, Wang L, Guo YS, Sun Z, Wei BY, Han YH, Liu J, et al: Ginsenoside-Rb2 inhibits dexamethasone-induced apoptosis through promotion of GPR120 induction in bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 24:781–790. 2015. View Article : Google Scholar : PubMed/NCBI
33	Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP and Teitelbaum SL: Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest. 116:2152–2160. 2006. View Article : Google Scholar : PubMed/NCBI
34	Papanicolaou DA and Vgontzas AN: Interleukin-6: The endocrine cytokine. J Clin Endocrinol Metab. 85:1331–1333. 2000. View Article : Google Scholar : PubMed/NCBI
35	Tanaka Y: Glucocorticoid and bone metabolism and disease. Clin Calcium. 23:229–235. 2013.(In Japanese). PubMed/NCBI